MedTrace Logo

Pharmacist-Led Education to Improve Neutropenic Precautions in Cancer Patients

NCT07690956 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-07-08

No results posted yet for this study

Summary

The goal of this clinical trial is to test whether pharmacist-led education can improve knowledge and adherence to neutropenic precautions and reduce infection rates in adult cancer patients receiving high-risk chemotherapy. The main questions it aims to answer are:

* Does pharmacist-led education improve patient knowledge of neutropenic fever prevention?
* Does it increase adherence to precautionary behaviors?
* Does it reduce the incidence of febrile neutropenia? Researchers will compare two groups: one receiving standard care and the other receiving additional education by a clinical pharmacist, to assess the impact on patient behavior and infection outcomes.

Participants will:

* Receive either standard care or a structured educational intervention that includes written materials, a counseling session, and an instructional video on neutropenic precautions.
* Complete knowledge and adherence surveys before and after the intervention.
* Be followed for 2-6 months to monitor adherence, infection rates, and treatment outcomes.

Conditions

Interventions

OTHER

Pharmacist-Led Neutropenic Education Package

The Pharmacist-Led Neutropenic Education Package (P-NEP) is a structured educational intervention designed to improve cancer patients' knowledge and adherence to neutropenic fever prevention measures during chemotherapy. It is delivered by a clinical pharmacist and consists of: Written educational materials in Arabic, adapted from the CDC's neutropenia infection prevention guidelines. A face-to-face counseling session that explains neutropenia, signs of infection, hygiene and dietary precautions, and appropriate actions in case of fever. An educational video (shared via URL) reinforcing key messages from the session. Patient support resources, including pharmacist contact information and summary instructions for reference. The intervention is administered prior to chemotherapy and reinforced with a follow-up assessment at 2 months. It is intended to empower patients to implement protective behaviors and report early signs of infection, ultimately aiming to reduce the incidence of FN.

Sponsors & Collaborators

  • Jordan University of Science and Technology

    lead OTHER

Principal Investigators

  • Abd Al-Rahman AR Awad, PharmD · Jordan University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-13
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690956 on ClinicalTrials.gov